Novartis Corp. v. Federal Trade Commission

How courts have described this case

Verbatim parenthetical descriptions written by other courts when citing this decision. Ranked by citation-network relevance.

• noting that Novartis did not dispute that the implied claim was “likely to deceive,” but not mentioning fraud, intentional deception, or bad faith
• upholding the Commission’s corrective order imposing disclosure requirements on drug manufacturer
• upholding the Commission’s corrective order imposing disclosure requirements on drug manufacturer
• “Although Doan’s is an effective pain reliever, there is no evidence that Doan’s is more effective than other pain relievers for back pain.”
• “Certain categories of information are presumptively material, including, but not limited to, express claims, claims significantly involving health or safety, and claims pertaining to the central characteristic of the product”
• evaluating a corrective remedy involving corrective statements under Central Hudson

Source: CourtListener parenthetical corpus (CC0).